This website uses cookies to enhance the user experience.
K

KRANE AS982 163 935

Purchase and sale
Limited company
Mellomvegen 65A 9007 TROMSØ, Norge

KRANE AS

Keywords

real estatesalesdevelopment

Organization

CEO
PK
Chairman of the board
Years since formation
25 years
since Jul 19, 2000
Type
Limited company
VAT registered
No
Number of employees
0

Ownership

Number of shares and share classes
109
2 share classes
Total number of shareholders
4
persons
Belongs to group of

Financials

Annual total result 2023
-273,516
NOK
Total equity 2023
40,269,221
NOK
Last update: Aug 29, 2024

Management

Management / administration

NameRoleShares
PK
Managing Director/CEO
9.17 %
directly

Board

NameRoleShares
Chairman-
Board Member
30.28 %
directly
Board Member
30.28 %
directly
Board Member
30.28 %
directly
PK
Board Member
9.17 %
directly

Others

NameRoleShares
R
REVISORKOMPANIET TROMSØ AS
Auditor-
A
AIDER AS
Accountant-

Top 10 individual shareholders

NameRoleShares
Board Member
30.28 %
directly
Board Member
30.28 %
directly
Board Member
30.28 %
directly
PK
Managing Director/CEO, Board Member
9.17 %
directly
Last update: Dec 2, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
Class B shares
33
30.28 %
Class B shares
33
30.28 %
Class B shares
33
30.28 %
PK
A-shares
10
9.17 %

Shares owned by the KRANE AS

NameShare classNumber of sharesShare
Ordinary shares
50
100 %
K
KRANE EIENDOM AS
Ordinary shares
100
100 %
Æ
ÆRFUGLVEIEN 6 AS
Ordinary shares
100,000
100 %
Æ
ÆRFUGLVEGEN UTVIKLING AS
Ordinary shares
450
45 %
P
PHASE TRANSITION AS
Ordinary shares
10,598
10.6 %
T
TØNSBERG ETATBYGG AS
Ordinary shares
956
0.74 %
Ordinary shares
1,100
0.58 %
S
SKI ETATBYGG AS
Ordinary shares
830
0.44 %
T
TRONDHEIM KONTOREIENDOM AS
Ordinary shares
500
0.43 %
Ordinary shares
3,315
0.4 %
L
LIFENESS AS
Preference shares
318
0.18 %
L
LYTIX BIOPHARMA AS
NO0010405780
67,860
0.17 %
NO0010985641
1,500
0.16 %
A
AMICOAT AS
NO0010799679
38,431
0.13 %
NO0011110223
40,000
0.13 %
P
PHARMASUM THERAPEUTICS AS
Ordinary shares
3,620
0.11 %
L
LITERATE AS
Ordinary shares
667
0.11 %
P
PHARMA HOLDINGS AS
NO0010797350
767
0.08 %
N
NRP EIENDOM 2016 INVEST AS
NO0010760820
20,000
0.05 %
Last update: May 24, 2024

Group structure

  • Total operating income 2023: NOK 0
    Operating profit 2023: NOK -1,019,880
    Employees: 0

Financials

in NOK

Summary

Year202320222021
Total operating income
0
40,000
123,024
Annual Total Result
-273,516
226,860
17,700,858
Total assets
44,081,605
45,026,079
44,776,060
Total liabilities
3,812,385
2,983,342
2,060,184
Total equity
40,269,221
42,042,737
42,715,876

P&L

Year202320222021
Total operating income
0
40,000
123,024
Total operating costs
1,019,880
563,492
1,884,856
Operating result
-1,019,880
-523,492
-1,761,833
Financial income/costs
747,187
862,029
19,409,349
Profit before tax
-272,693
338,536
17,647,516
Total tax & extraordinary income/cost
823
111,676
-53,342
Annual Total Result
-273,516
226,860
17,700,858

Balance overview

Year202320222021
Total fixed assets
27,448,237
31,033,194
26,233,193
Total current assets
16,633,368
13,992,885
18,542,867
Total assets
44,081,605
45,026,079
44,776,060
Short term debt
3,812,385
2,983,342
2,060,184
Long term debt
0
0
0
Total liabilities
3,812,385
2,983,342
2,060,184
Contributed capital
380,737
380,737
380,737
Retained earnings
39,888,484
41,662,000
42,335,139
Total equity
40,269,221
42,042,737
42,715,876
Total equity and liabilities
44,081,605
45,026,079
44,776,060

Classification

Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
F
Main industrial area
Construction
41
Activity
Construction of buildings
41.1
Main industrial group
Development of building projects
41.10
Industrial group
Development of building projects
41.109
Industrial group
Other development and sale of real estate